Physician profile
Ali Shahbaz
NPI 1336870138
$413,145.02
in general payments reported to CMS, 2019-2025
30 companies · $260K in 2025
The $260K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $397 · 2023: $22K · 2024: $130K · 2025: $260K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $197K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $135K · Travel and Lodging: $30K · Food and Beverage: $26K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $21K · Honoraria: $2,281 · Education: $276 · Gift: $33.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $197,390.34 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $135,385.01 |
| Travel and Lodging | $30,043.68 |
| Food and Beverage | $26,039.56 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $21,299.00 |
| Honoraria | $2,280.87 |
| Education | $276.02 |
| Gift | $33.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $104,155.48 | 2023-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $57,792.74 | 2022-2025 | Anzupgo, Adbry, Spevigo |
| Galderma Laboratories, L.P. | $56,834.96 | 2023-2025 | Nemluvio, Aklief, Oracea |
| Arcutis Biotherapeutics, INC. | $49,327.20 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $45,363.47 | 2023-2025 | Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $24,338.28 | 2023-2025 | |
| Abbvie INC. | $13,323.18 | 2022-2025 | Rinvoq, Botox, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $13,137.67 | 2022-2025 | Sotyktu |
| Amgen INC. | $10,510.40 | 2023-2025 | Otezla, Otezla |
| Eli Lilly and Company | $6,807.43 | 2024-2025 | Ebglyss, Mounjaro |
| Incyte Corporation | $6,610.39 | 2023-2025 | Opzelura |
| Pfizer INC. | $5,056.40 | 2024-2025 | |
| Dermavant Sciences, INC. | $4,405.36 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $3,425.58 | 2023-2025 | Tremfya |
| Almirall LLC | $2,327.08 | 2024-2025 | Klisyri, Seysara |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,166.93 | 2023-2025 | Tremfya |
| Janssen Pharmaceuticals, INC | $2,085.00 | 2024 | |
| Organon LLC | $1,887.94 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $1,014.04 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $777.39 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $575.29 | 2022-2025 | |
| Merz North America, INC. | $381.73 | 2023-2025 | Xeomin |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $199.15 | 2022-2025 | Cabtreo, Arazlo, Siliq |
| Takeda Pharmaceuticals U.S.A., INC. | $150.64 | 2025 | |
| Mayne Pharma Commercial LLC | $142.28 | 2023-2025 | |
| Biofrontera INC. | $124.82 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $123.62 | 2022-2025 | |
| Botanix Sb INC | $44.03 | 2025 | Sofdra |
| Cipher Pharmaceuticals US LLC | $29.77 | 2025 | Natroba, Spinosad |
| Revance Therapeutics, INC. | $26.77 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Shahbaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.